Segall Bryant & Hamill’s Haemonetics HAE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.11M | Sell |
68,092
-5,900
| -8% | -$379K | 0.06% | 319 |
|
|
2026
Q1 | $4.17M | Buy |
73,992
+50,412
| +214% | +$3.28M | 0.06% | 331 |
|
|
2025
Q4 | $1.89M | Sell |
23,580
-68
| -0.3% | -$4.57K | 0.03% | 445 |
|
|
2025
Q3 | $1.15M | Buy |
23,648
+4,302
| +22% | +$266K | 0.02% | 494 |
|
|
2025
Q2 | $1.44M | Sell |
19,346
-2,064
| -10% | -$137K | 0.02% | 471 |
|
|
2025
Q1 | $1.36M | Buy |
+21,410
| New | +$1.46M | 0.02% | 474 |
|
|
2024
Q4 | – | Sell |
-62,621
| Closed | -$5.03M | – | 602 |
|
|
2024
Q3 | $5.03M | Buy |
62,621
+407
| +0.7% | +$32.9K | 0.07% | 330 |
|
|
2024
Q2 | $5.15M | Buy |
+62,214
| New | +$5.47M | 0.09% | 287 |
|
|
2021
Q2 | – | Sell |
-65,691
| Closed | -$7.3M | – | 793 |
|
|
2021
Q1 | $7.3M | Sell |
65,691
-58,689
| -47% | -$7.26M | 0.07% | 268 |
|
|
2020
Q4 | $14.8M | Sell |
124,380
-8,278
| -6% | -$891K | 0.16% | 153 |
|
|
2020
Q3 | $11.6M | Buy |
132,658
+88,719
| +202% | +$7.75M | 0.16% | 146 |
|
|
2020
Q2 | $3.93M | Buy |
43,939
+36,423
| +485% | +$3.68M | 0.07% | 250 |
|
|
2020
Q1 | $749K | Buy |
+7,516
| New | +$815K | 0.02% | 499 |
|
|
2018
Q3 | – | Sell |
-38,368
| Closed | -$3.44M | – | 856 |
|
|
2018
Q2 | $3.44M | Sell |
38,368
-28,067
| -42% | -$2.37M | 0.05% | 350 |
|
|
2018
Q1 | $4.86M | Sell |
66,435
-119,679
| -64% | -$8.21M | 0.11% | 201 |
|
|
2017
Q4 | $10.8M | Sell |
186,114
-12,576
| -6% | -$662K | 0.24% | 111 |
|
|
2017
Q3 | $8.91M | Sell |
198,690
-3,730
| -2% | -$155K | 0.21% | 119 |
|
|
2017
Q2 | $7.99M | Buy |
202,420
+63,748
| +46% | +$2.62M | 0.19% | 124 |
|
|
2017
Q1 | $5.63M | Buy |
138,672
+19,908
| +17% | +$777K | 0.14% | 163 |
|
|
2016
Q4 | $4.77M | Buy |
118,764
+1,447
| +1% | +$54.6K | 0.12% | 182 |
|
|
2016
Q3 | $4.25M | Buy |
117,317
+49,865
| +74% | +$1.71M | 0.11% | 198 |
|
|
2016
Q2 | $1.96M | Buy |
67,452
+16,645
| +33% | +$503K | 0.05% | 292 |
|
|
2016
Q1 | $1.78M | Buy |
+50,807
| New | +$1.64M | 0.04% | 307 |
|
|
2015
Q3 | – | Sell |
-87,108
| Closed | -$3.6M | – | 554 |
|
|
2015
Q2 | $3.6M | Buy |
87,108
+1,015
| +1% | +$42.8K | 0.08% | 259 |
|
|
2015
Q1 | $3.87M | Sell |
86,093
-175
| -0.2% | -$7.32K | 0.09% | 247 |
|
|
2014
Q4 | $3.23M | Buy |
86,268
+17,865
| +26% | +$654K | 0.07% | 270 |
|
|
2014
Q3 | $2.39M | Buy |
68,403
+54,510
| +392% | +$1.95M | 0.06% | 289 |
|
|
2014
Q2 | $490K | Sell |
13,893
-28,011
| -67% | -$936K | 0.01% | 439 |
|
|
2014
Q1 | $1.37M | Sell |
41,904
-12,038
| -22% | -$460K | 0.03% | 304 |
|
|
2013
Q4 | $2.27M | Sell |
53,942
-3,609
| -6% | -$149K | 0.05% | 259 |
|
|
2013
Q3 | $2.29M | Buy |
57,551
+759
| +1% | +$31.8K | 0.06% | 257 |
|
|
2013
Q2 | $2.35M | Buy |
+56,792
| New | +$2.3M | 0.06% | 249 |
|
Other funds holding HAE
AI
Segall Bryant & Hamill's HAE Position: Q2 2026 in Review
Segall Bryant & Hamill reduced its Haemonetics (HAE) stake by 8% in Q2 2026, selling an estimated $379K and leaving 68,092 shares worth $5.11M. The position accounts for 0.06% of the portfolio, ranked #319.
Segall Bryant & Hamill first reported a position in HAE in Q2 2013 and has held it in 32 quarters since. The position peaked at $14.8M in Q4 2020. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.
- Segall Bryant & Hamill held 68,092 shares of Haemonetics worth $5.11M as of Q2 2026.
- Segall Bryant & Hamill sold 5,900 Haemonetics shares in Q2 2026, an estimated $379K.
- Haemonetics made up 0.06% of Segall Bryant & Hamill's portfolio in Q2 2026, its #319 holding.
- Segall Bryant & Hamill first reported a position in Haemonetics in Q2 2013 and has held it in 32 quarters since.
- Segall Bryant & Hamill's Haemonetics position peaked at $14.8M in Q4 2020.
- 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.
Based on Segall Bryant & Hamill's 13F filing for Q2 2026, filed 12 Aug 2026.